The efficacy of cinacalcet in the treatment of hyperparathyroidism in Turkish hemodialysis patient population

WOS: 000393291900012OBJECTIVE: Cinacalcet reduces parathyroid hormone levels by increasing the sensitivity of the parathyroid gland to calcium. in this study, we firstly aimed to evaluate the efficacy of cinacalcet in Turkish hemodialysis patients. MATERIAL and METHODS: 4483 hemodialysis patients were screened and 469 patients who had used cinacalcet were included in the study. the patients were divided into 4 groups according to drug usage durations (Group 1: 3 months, Group 2: 6 months, Group 3: 9 months and Group 4: 12 months). the patients' Parathormone, Ca, P and CaxP levels at the 3rd, 6th, 9th and 12th months were compared to the start of treatment and previous months. RESULTS: the levels of Parathormone, Ca, P and CaxP significantly decreased compared to their initial levels in all groups (from 1412 pg/ml to 1222 pg/mL for Parathormone, p< 0,001) in the 3rd month. However, this reduction was not continued in the subsequent months (Parathormone: 1381 pg/ml for the 12th month). CONCLUSION: Cinacalcet may not provide adequate benefit in control of hyperparathyroidism in Turkish hemodialysis patient population

Hematological Parameters and Clinical Features in Patients with Advanced Chronic Kidney Disease

Background Hematological parameters like red cell distribution width (RDW) and mean platelet volume (MPV) were reported to be associated with inflammation, atherosclerosis, and chronic kidney disease (CKD) progression. In this study, we evaluated RDW and MPV along with clinical features in patients with advanced CKD. We also aimed to detect clues for causative relations concerning these parameters, renal function and comorbiditics

Complementary and alternative medicine use among kidney transplant patients in Turkey; prevalence, clinical features and outcomes

Introduction: Our aim in this study to evaluate the prevalence, types of complementary and alternative medicine (CAM) and outcomes among patients kidney transplant recipients in our country.Methods: This is a cross-sectional study was conducted from May 2019 to May 2020 in the nephrology outpatient clinics of five different university hospital. They answered a self-administered a survey questionnaire, this form is included questions on socio-demographic and clinical features and on the CAM therapies.Results: A total of 830 patients (496 [59.8%] males, 334 [40.2%] females; mean age 43.9 +/- 9.4 years) kidney transplantation recruited for the study. One hundred ninety-two (22.8%) of the patients reported the use of one or more forms of CAM. Meanwhile, 64.5% of CAM users did not report their CAM therapies to their physicians. There was a significant correlates for CAM users were older age (P = 0.00; odds ratio (OR) = 0.76; 95% CI = 0.88-0.93), occupational status (P = 0.045) and monthly income (P = 0.021; odds ratio (OR) = 2.18; 95% CI = 1.42-3.3).Conclusions: We determined that every five of one kidney transplant patients were using one type of CAM. Some of these CAMs are potentially harmful and may affect patient compliance to immunosuppressive therapies. Physicians should ask questions about CAM to patients on visit days and should explained their knowledge about CAM therapies

Relationship between disease awareness and severity of kidney disease in autosomal dominant polycystic kidney disease patients

Introduction Polycystic kidney disease (PKD) is responsible for 5%-10% of end-stage renal disease. We examined the relationship between renal and extrarenal findings, disease severity, and the level of consciousness of PKD patients. Methods Patients were asked to answer the questionnaire about PKD. Disease severity was determined according to estimated glomerular filtration rate, and disease awareness was assessed by adapting the Disease Perception Scale to PKD. Awareness of patients was evaluated comparatively with chronic kidney disease stage, age, region, and symptoms. Results One out of five patients does not know that this disease is inherited. Mean awareness scores of the patients decreased significantly with increasing age. Awareness scores were significantly higher in patients with flank pain, hematuria, and urinary tract stones. Conclusion Although PKD is the most common hereditary kidney disease, the rate of patients' knowledge on this subject is low. Increased awareness might lead to better treatment in those patients